🔴 MPAL.L is trading 5% down today on profit-taking after sharp post-approval rally

MPAL.L is trading approximately 5% down at $4.35 as the stock undergoes volatility normalization following a significant multi-day surge.

• The recent decline follows a move of more than 50% triggered by UK regulatory news regarding Novo Nordisk’s oral GLP-1 product, which directly benefits MedPal AI’s New Health weight-management platform.
• Current weakness is attributed to profit-taking after the recent rally rather than fundamental shifts, with no new negative company-specific updates reported in the latest session.